Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

49.73USD
28 Sep 2016
Change (% chg)

$0.26 (+0.53%)
Prev Close
$49.47
Open
$49.70
Day's High
$49.85
Day's Low
$49.61
Volume
115,866
Avg. Vol
1,122,608
52-wk High
$66.55
52-wk Low
$48.01

Latest Key Developments (Source: Significant Developments)

MDxHealth and Teva Pharmaceuticals sign distribution deal
Wednesday, 31 Aug 2016 01:06am EDT 

Mdxhealth SA : MDxHealth and Teva Pharmaceuticals sign distribution agreement for SelectMDx in Israel .Teva Pharmaceuticals will be exclusive distributor of selectMDx for prostate cancer test in Israel.  Full Article

Moody's says Teva's loss of two copaxone patents is credit negative
Thursday, 25 Aug 2016 02:33pm EDT 

Moody's Ratings : Teva's loss of two copaxone patents is credit negative .Moody's on Teva Pharmaceutical - there is no change to Teva Pharmaceutical Industries LTD Baa2 senior unsecured rating or stable outlook.  Full Article

Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone
Wednesday, 24 Aug 2016 05:46pm EDT 

Teva Pharmaceutical Industries Ltd : Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone 40 mg .Teva plans to appeal to United States Court of appeals for Federal Circuit.  Full Article

Mylan invalidates two of Teva's Copaxone patents
Wednesday, 24 Aug 2016 04:47pm EDT 

Mylan Nv : Mylan invalidates two of Teva's Copaxone® 40 mg/ml patents via U.S. Patent and Trademark Office's Inter Partes Review proceeding . Decision by PTAB on Mylan's third petition seeking Inter Partes Review of U.S. Patent no. 8,696,302 is expected on or before September 1, 2016 . U.S. PTO has ruled in favor of Mylan in its Inter Partes Review proceeding and found all claims of two related Copaxone 40 mg/ml patents to be unpatentable . Announced that U.S. Patent and Trademark Office (PTO) has ruled in favor of mylan in its Inter Partes Review (IPR) proceeding .Mylan Nv says "Mylan will proceed with pursuing all avenues to challenge '776 patent".  Full Article

Teva Canada says daily COPAXONE 20 mg/ml will continue to be available
Tuesday, 23 Aug 2016 07:59am EDT 

Teva Pharmaceutical Industries Ltd : Teva Canada Innovation says in addition to newly approved dose, daily COPAXONE 20 mg/ml will continue to be available .Times-A-Week COPAXONE® 40mg/ml by Health Canada.  Full Article

Allergan Equico reports 9.9 pct stake in Teva Pharmaceutical
Monday, 8 Aug 2016 06:15pm EDT 

Allergan :Reports a stake of 9.9 pct in Teva Pharmaceutical Industries Ltd as of July 27, 2016 - SEC filing.  Full Article

Teva Pharm CEO warns on launching generic Copaxone
Thursday, 4 Aug 2016 08:45am EDT 

Teva Pharmaceutical Industries Ltd : Teva Pharm CEO Erez Vigodman said on Thursday that any generic launch of the company's blockbuster multiple sclerosis drug Copaxone prior to court ruling, which is likely to come by the second half of 2018, "would be at risk". Further company coverage: [TEVA.TA] (Reporting by Ari Rabinovitch and Steven Scheer) ((ari.rabinovitch@thomsonreuters.com;)).  Full Article

Teva Q2 non-GAAP earnings per share $1.25
Thursday, 4 Aug 2016 07:00am EDT 

Teva Pharmaceutical Industries Ltd Sees Revenues For 2016 To Be $22.0 : Teva reports second quarter 2016 results . Sees fy 2016 revenue $22 billion to $22.5 billion . 22.5 billion. . Sees fy 2016 non-gaap earnings per share $5.20 to $5.40 . Q2 revenue rose 1 percent to $5.0 billion . Quarter ended june 30 non-gaap eps $1.25 . Quarter ended june 30 non-gaap eps adjusted to exclude impact of december 2015 equity offerings of $1.43 . Generic medicines revenues in q2 of 2016 amounted to $2.3 billion, a decrease of 7% . Specialty medicines revenues in q2 of 2016 amounted to $2.3 billion, an increase of 9% . Q2 gaap earnings per share $0.20 . Q2 earnings per share view $1.46, revenue view $5.99 billion -- Thomson Reuters I/B/E/S .Fy2016 earnings per share view $5.51, revenue view $22.84 billion -- Thomson Reuters I/B/E/S.  Full Article

Allergan announces sale of Anda distribution business to Teva
Wednesday, 3 Aug 2016 07:00am EDT 

Allergan Plc : For Q2 of 2016, Anda is expected to contribute approximately $375 million in net revenues excluding sales of Allergan's branded products . For Q2 of 2016, Anda is expected to contribute approximately $0.05 in earnings per share . Allergan announces sale of Anda distribution business to Teva Pharmaceuticals . Allergan Plc says deal valued at $500 million . Anda to be reported as discontinued operations beginning with Q2 2016 earnings report on August 8, 2016 .For full year 2016, Anda is expected to contribute approximately $1.5 billion in third-party net revenue and approximately $0.15 in EPS.  Full Article

Moody's downgrades Teva's ratings to Baa2; outlook stable
Tuesday, 2 Aug 2016 04:30pm EDT 

Moody's: Moody's downgrades Teva's ratings to Baa2; outlook stable .Moody's on Teva - Moody's could upgrade ratings if Teva successfully integrates Allergan generics business and realizes significant synergies.  Full Article

BRIEF-Teva launches generic epzicom tablets in the U.S.

* Teva announces launch of generic epzicom tablets in the United States Source text for Eikon: Further company coverage: